Emerging pro-drug and nano-drug strategies for gemcitabine-based cancer therapy
Asian Journal of Pharmaceutical Sciences, 2022 Gemcitabine has been extensively applied in treating various solid tumors. Nonetheless, the clinical performance of gemcitabine is severely restricted by its unsatisfactory pharmacokinetic parameters and easy deactivation mainly because of its rapid ...
Haijie Han, Yueyang Zhong, Yue Huang
exaly +3 more sources
Tislelizumab combined with gemcitabine plus cisplatin for muscle-invasive upper tract urothelial carcinoma: A retrospective single-center cohort analysis [PDF]
Journal of International Medical ResearchObjective Gemcitabine plus cisplatin is the standard adjuvant regimen for postoperative management of muscle-invasive upper tract urothelial carcinoma. This study investigated whether adding tislelizumab to gemcitabine plus cisplatin improves outcomes in
Jingwen Zhang +4 more
doaj +2 more sources
The synthesis of gemcitabine [PDF]
Carbohydrate Research, 2014 Gemcitabine is a fluorinated nucleoside currently administered against a number of cancers. It consists of a cytosine base and a 2-deoxy-2,2-difluororibose sugar. The synthetic challenges associated with the introduction of the fluorine atoms, as well as with nucleobase introduction of 2,2-difluorinated sugars, combined with the requirement to have an ...
Brown, Kylie +3 more
openaire +4 more sources
Study of the Efficacy and Multidrug Resistance Using Gold Nanoparticles-Based Drug Delivery Versus Conventional Chemotherapy in Non-Small-Cell Lung Cancer Cell Line [PDF]
Research in Oncology, 2021 Background: Cisplatin is the main chemotherapy in the treatment of non-small-cell lung cancer (NSCLC) combined with gemcitabine or other agents. Aim: The aim of this study was to evaluate in vitro the anti-tumor efficacy and multidrug resistance of gold
Aida A. Guemei +4 more
doaj +1 more source
A Novel Strategy to Improve the Therapeutic Efficacy of Gemcitabine for Non-Small Cell Lung Cancer by the Tumor-Penetrating Peptide iRGD. [PDF]
PLoS ONE, 2015 Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, comprising approximately 75-80% of all lung cancers. Gemcitabine is an approved chemotherapy drug for NSCLC. The objective of this study was to develop a novel strategy to improve
Qing Zhang +5 more
doaj +1 more source
Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer. [PDF]
PLoS ONE, 2012 Gemcitabine (Gem) has limited clinical benefits in pancreatic ductal adenocarcinoma (PDAC). The present study investigated combinations of gemcitabine with antiangiogenic agents of various mechanisms for PDAC, including bevacizumab (Bev), sunitinib (Su ...
Niranjan Awasthi +4 more
doaj +1 more source
Activity of combined gemcitabine therapy on treatment of planocellular carcinoma: A pilot study [PDF]
Archive of Oncology, 2004 BACKGROUND: Drug-orientated, pilot study was conducted to estimate the activity of gemcitabine on treatment of head and neck and lung planocellular carcinoma in combination with either radiotherapy or chemotherapy.
Šćepanović Danijela S. +2 more
doaj +1 more source
Clinical and Translational Science, 2020 This study intends to compare short‐term efficacy of 12 chemotherapy regimens in treatment of advanced non‐small cell lung cancer (NSCLC) by a network meta‐analysis (NMA).
Bei‐Bei Zhang +6 more
doaj +1 more source
Cell Death and Disease, 2021 The poor prognosis of pancreatic cancer is primarily due to the development of resistance to therapies, including gemcitabine. The long noncoding RNA PVT1 (lncRNA PVT1) has been shown to interact with enhancer of zeste 2 polycomb repressive complex 2 ...
Yan Sun +5 more
doaj +1 more source
Pharmaceuticals, 2022 Gemcitabine is a chemotherapeutic used clinically to treat a variety of cancers. However, because it lacks tumor cell specificity, gemcitabine may cause off-target cytotoxicity and adversely impact patients.
Jianjun Qi +8 more
doaj +1 more source